초록 ▼

This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: wherein: R1is H, alkyl, alkanoyl or the radical Ar; R2is H or alkyl; R3is alkoxy, NH2,alkylamino, dialkylamino, amino substituted by the

This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: wherein: R1is H, alkyl, alkanoyl or the radical Ar; R2is H or alkyl; R3is alkoxy, NH2,alkylamino, dialkylamino, amino substituted by the radical Ar, alkyl, alkenyl, alkynyl, or the radicals Ar or ArO--; R4is H, alkyl or the radical Ar; R5is H or alkyl or the radical Ar; or a pharmaceutically acceptable salt or ester form thereof; Ar is an optionally substituted phenyl radical; and n is 0 or 1, or a pharmaceutically acceptable salt or ester form thereof, with the methods particularly including the use of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also known as retigabine.

대표청구항 ▼

This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: wherein: R1is H, alkyl, alkanoyl or the radical Ar; R2is H or alkyl; R3is alkoxy, NH2,alkylamino, dialkylamino, amino substituted by the

This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: wherein: R1is H, alkyl, alkanoyl or the radical Ar; R2is H or alkyl; R3is alkoxy, NH2,alkylamino, dialkylamino, amino substituted by the radical Ar, alkyl, alkenyl, alkynyl, or the radicals Ar or ArO--; R4is H, alkyl or the radical Ar; R5is H or alkyl or the radical Ar; or a pharmaceutically acceptable salt or ester form thereof; Ar is an optionally substituted phenyl radical; and n is 0 or 1, or a pharmaceutically acceptable salt or ester form thereof, with the methods particularly including the use of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also known as retigabine. oxy group of 6 to 10 carbons; R4is a substituent at the C-4 position, C-5 position, C-6 position or C-7 position of the benzofuran ring and represents: R4awhich represents hydrogen, a nitro group, a cyano group, a halogen atom, an alkenyl group of 2 to 5 carbons, an alkynyl group of 2 to 5 carbons, an aryl group of 6 to 10 carbons, --OR7(wherein R7represents hydrogen, a cycloalkyl group of 3 to 7 carbons, an aryl group of 6 to 10 carbons, an optionally halogen-substituted alkylsulfonyl group of 1 to 4 carbons or an arylsulfonyl group of 6 to 10 carbons), --O--CO--R8(wherein R8represents hydrogen, an alkyl group of 1 to 4 carbons, an aryl group of 6 to 10 carbons, or an aralkyl group of 7 to 20 carbons), --NR9R10(wherein R9and R10each independently represents hydrogen, an alkyl group of 1 to 4 carbons, an aralkyl group of 7 to 20 carbons, a phenyl group, --SO2--R11(wherein R11represents an optionally halogen-substituted alkyl group of 1 to 12 carbons, an aryl group of 6 to 10 carbons, or an aralkyl group of 7 to 20 carbons) or --CO--R12(wherein R12represents hydrogen, an alkyl group of 1 to 12 carbons, an aryl group of 6 to 10 carbons, an aralkyl group of 7 to 20 carbons, an alkoxy group of 1 to 10 carbons, an aryloxy group of 6 to 10 carbons, or an aralkyloxy group of 7 to 20 carbons)), --CO--R13(wherein R13represents hydrogen, --OH, an alkyl group of 1 to 4 carbons, an aryl group of 6 to 10 carbons, an alkoxy group of 1 to 4 carbons, an aryloxy group of 6 to 10 carbons or an aralkyloxy group of 7 to 20 carbons) or --CO--NR14R15(wherein R14and R15each independently represents hydrogen, an alkyl group of 1 to 4 carbons, a cycloalkyl group of 3 to 7 carbons, an aryl group of 6 to 10 carbons, or an aralkyl group of 7 to 20 carbons); R4bwhich represents a saturated or unsaturated alkoxy group of 1 to 6 carbons optionally substituted with 1 to 3 groups selected from the group consisting of halogens, cycloalkyl groups of 3 to 7 carbons, phenyl, naphthyl, --OR16(wherein R16represents hydrogen, an alkyl group of 1 to 4 carbons, a phenyl group, a naphthyl group, or a benzyl group), --O--CO--R16(wherein R16represents hydrogen, an alkyl group of 1 to 4 carbons, a phenyl group, a naphthyl group, or a benzyl group), --NR17R18(wherein R17and R18each independently represents hydrogen, an alkyl group of 1 to 4 carbons, an alkylsulfonyl group of 1 to 4 carbons, a phenylsulfonyl group, an aminosulfonyl group, a methylaminosulfonyl group, a dimethylaminosulfonyl group, a diethylaminosulfonyl group, or an alkyl group of 1 to 4 carbons substituted with 1 or 2 groups selected from among phenyl, phenoxy, and hydroxyl), --NH--CO--R19(wherein R19represents hydrogen, an alkyl group of 1 to 4 carbons, a phenyl group, a naphthyl group, a benzyl group, an alkoxy group of 1 to 4 carbons or a benzyloxy group), --CO--R20(wherein R20represents hydrogen, an alkoxy group of 1 to 4 carbons, a phenoxy group, a benzyloxy group or --OR21(wherein R21represents hydrogen) and --CO--NR22R23(wherein R22and R23each independently represents hydrogen, an alkyl group of 1 to 4 carbons, or a benzyl group); or R4Cwhich represents an alkyl group of 1 to 4 carbons optionally substituted with 1 to 3 groups selected from the group consisting of halogens, cycloalkyl groups of 3 to 7 carbons, phenyl, naphthyl, --SH, --OR16(wherein R16represents hydrogen, an alkyl group of 1 to 4 carbons, a phenyl group, a naphthyl group, or a benzyl group), --O--CO--R16(wherein R16represents hydrogen, an alk